CRL4<sup>CDT2</sup> Targets CHK1 for PCNA-Independent Destruction

Jiwon Huh(Washington University in St. Louis), Helen Piwnica‐Worms(Washington University in St. Louis)

Molecular and Cellular Biology

October 30, 2012

10.1128/mcb.00847-12

Cited by 79

Related Papers

The Chk1 Protein Kinase and the Cdc25C Regulatory Pathways Are Targets of the Anticancer Agent UCN-01

|Journal of Biological Chemistry|2000|541

Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models

|Journal of Clinical Investigation|2012|222

A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies

|Cancer Chemotherapy and Pharmacology|2010|69

p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer

|Breast Cancer Research|2016|50